Inhibition of pyruvate dehydrogenase kinase 2 protects against hepatic steatosis through modulation of tricarboxylic acid cycle anaplerosis and ketogenesis

Younghoon Go, Ji Yun Jeong, Nam Ho Jeoung, Jae Han Jeon, Bo Yoon Park, Hyeon Ji Kang, Chae Myeong Ha, Young Keun Choi, Sun Joo Lee, Hye Jin Ham, Byung Gyu Kim, Keun Gyu Park, So Young Park, Chul Ho Lee, Cheol Soo Choi, Tae Sik Park, W. N. Paul Lee, Robert Harris, In Kyu Lee

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Hepatic steatosis is associated with increased insulin resistance and tricarboxylic acid (TCA) cycle flux, but decreased ketogenesis and pyruvate dehydrogenase complex (PDC) flux. This study examined whether hepatic PDC activation by inhibition of pyruvate dehydrogenase kinase 2 (PDK2) ameliorates these metabolic abnormalities. Wildtype mice fed a high-fat diet exhibited hepatic steatosis, insulin resistance, and increased levels of pyruvate, TCA cycle intermediates, and malonyl-CoA but reduced ketogenesis and PDC activity due to PDK2 induction. Hepatic PDC activation by PDK2 inhibition attenuated hepatic steatosis, improved hepatic insulin sensitivity, reduced hepatic glucose production, increased capacity for β-oxidation and ketogenesis, and decreased the capacity for lipogenesis. These results were attributed to altered enzymatic capacities and a reduction in TCA anaplerosis that limited the availability of oxaloacetate for the TCA cycle, which promoted ketogenesis. The current study reports that increasing hepatic PDC activity by inhibition of PDK2 ameliorates hepatic steatosis and insulin sensitivity by regulating TCA cycle anaplerosis and ketogenesis. The findings suggest PDK2 is a potential therapeutic target for nonalcoholic fatty liver disease.

Original languageEnglish (US)
Pages (from-to)2876-2887
Number of pages12
JournalDiabetes
Volume65
Issue number10
DOIs
StatePublished - Oct 1 2016

Fingerprint

Citric Acid Cycle
Pyruvate Dehydrogenase Complex
Liver
Insulin Resistance
Tricarboxylic Acids
Malonyl Coenzyme A
pyruvate dehydrogenase (acetyl-transferring) kinase
Oxaloacetic Acid
Lipogenesis
High Fat Diet
Pyruvic Acid
Glucose

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Inhibition of pyruvate dehydrogenase kinase 2 protects against hepatic steatosis through modulation of tricarboxylic acid cycle anaplerosis and ketogenesis. / Go, Younghoon; Jeong, Ji Yun; Jeoung, Nam Ho; Jeon, Jae Han; Park, Bo Yoon; Kang, Hyeon Ji; Ha, Chae Myeong; Choi, Young Keun; Lee, Sun Joo; Ham, Hye Jin; Kim, Byung Gyu; Park, Keun Gyu; Park, So Young; Lee, Chul Ho; Choi, Cheol Soo; Park, Tae Sik; Paul Lee, W. N.; Harris, Robert; Lee, In Kyu.

In: Diabetes, Vol. 65, No. 10, 01.10.2016, p. 2876-2887.

Research output: Contribution to journalArticle

Go, Y, Jeong, JY, Jeoung, NH, Jeon, JH, Park, BY, Kang, HJ, Ha, CM, Choi, YK, Lee, SJ, Ham, HJ, Kim, BG, Park, KG, Park, SY, Lee, CH, Choi, CS, Park, TS, Paul Lee, WN, Harris, R & Lee, IK 2016, 'Inhibition of pyruvate dehydrogenase kinase 2 protects against hepatic steatosis through modulation of tricarboxylic acid cycle anaplerosis and ketogenesis', Diabetes, vol. 65, no. 10, pp. 2876-2887. https://doi.org/10.2337/db16-0223
Go, Younghoon ; Jeong, Ji Yun ; Jeoung, Nam Ho ; Jeon, Jae Han ; Park, Bo Yoon ; Kang, Hyeon Ji ; Ha, Chae Myeong ; Choi, Young Keun ; Lee, Sun Joo ; Ham, Hye Jin ; Kim, Byung Gyu ; Park, Keun Gyu ; Park, So Young ; Lee, Chul Ho ; Choi, Cheol Soo ; Park, Tae Sik ; Paul Lee, W. N. ; Harris, Robert ; Lee, In Kyu. / Inhibition of pyruvate dehydrogenase kinase 2 protects against hepatic steatosis through modulation of tricarboxylic acid cycle anaplerosis and ketogenesis. In: Diabetes. 2016 ; Vol. 65, No. 10. pp. 2876-2887.
@article{dcf538de48ab4b07b512e82fa20d2e98,
title = "Inhibition of pyruvate dehydrogenase kinase 2 protects against hepatic steatosis through modulation of tricarboxylic acid cycle anaplerosis and ketogenesis",
abstract = "Hepatic steatosis is associated with increased insulin resistance and tricarboxylic acid (TCA) cycle flux, but decreased ketogenesis and pyruvate dehydrogenase complex (PDC) flux. This study examined whether hepatic PDC activation by inhibition of pyruvate dehydrogenase kinase 2 (PDK2) ameliorates these metabolic abnormalities. Wildtype mice fed a high-fat diet exhibited hepatic steatosis, insulin resistance, and increased levels of pyruvate, TCA cycle intermediates, and malonyl-CoA but reduced ketogenesis and PDC activity due to PDK2 induction. Hepatic PDC activation by PDK2 inhibition attenuated hepatic steatosis, improved hepatic insulin sensitivity, reduced hepatic glucose production, increased capacity for β-oxidation and ketogenesis, and decreased the capacity for lipogenesis. These results were attributed to altered enzymatic capacities and a reduction in TCA anaplerosis that limited the availability of oxaloacetate for the TCA cycle, which promoted ketogenesis. The current study reports that increasing hepatic PDC activity by inhibition of PDK2 ameliorates hepatic steatosis and insulin sensitivity by regulating TCA cycle anaplerosis and ketogenesis. The findings suggest PDK2 is a potential therapeutic target for nonalcoholic fatty liver disease.",
author = "Younghoon Go and Jeong, {Ji Yun} and Jeoung, {Nam Ho} and Jeon, {Jae Han} and Park, {Bo Yoon} and Kang, {Hyeon Ji} and Ha, {Chae Myeong} and Choi, {Young Keun} and Lee, {Sun Joo} and Ham, {Hye Jin} and Kim, {Byung Gyu} and Park, {Keun Gyu} and Park, {So Young} and Lee, {Chul Ho} and Choi, {Cheol Soo} and Park, {Tae Sik} and {Paul Lee}, {W. N.} and Robert Harris and Lee, {In Kyu}",
year = "2016",
month = "10",
day = "1",
doi = "10.2337/db16-0223",
language = "English (US)",
volume = "65",
pages = "2876--2887",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "10",

}

TY - JOUR

T1 - Inhibition of pyruvate dehydrogenase kinase 2 protects against hepatic steatosis through modulation of tricarboxylic acid cycle anaplerosis and ketogenesis

AU - Go, Younghoon

AU - Jeong, Ji Yun

AU - Jeoung, Nam Ho

AU - Jeon, Jae Han

AU - Park, Bo Yoon

AU - Kang, Hyeon Ji

AU - Ha, Chae Myeong

AU - Choi, Young Keun

AU - Lee, Sun Joo

AU - Ham, Hye Jin

AU - Kim, Byung Gyu

AU - Park, Keun Gyu

AU - Park, So Young

AU - Lee, Chul Ho

AU - Choi, Cheol Soo

AU - Park, Tae Sik

AU - Paul Lee, W. N.

AU - Harris, Robert

AU - Lee, In Kyu

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Hepatic steatosis is associated with increased insulin resistance and tricarboxylic acid (TCA) cycle flux, but decreased ketogenesis and pyruvate dehydrogenase complex (PDC) flux. This study examined whether hepatic PDC activation by inhibition of pyruvate dehydrogenase kinase 2 (PDK2) ameliorates these metabolic abnormalities. Wildtype mice fed a high-fat diet exhibited hepatic steatosis, insulin resistance, and increased levels of pyruvate, TCA cycle intermediates, and malonyl-CoA but reduced ketogenesis and PDC activity due to PDK2 induction. Hepatic PDC activation by PDK2 inhibition attenuated hepatic steatosis, improved hepatic insulin sensitivity, reduced hepatic glucose production, increased capacity for β-oxidation and ketogenesis, and decreased the capacity for lipogenesis. These results were attributed to altered enzymatic capacities and a reduction in TCA anaplerosis that limited the availability of oxaloacetate for the TCA cycle, which promoted ketogenesis. The current study reports that increasing hepatic PDC activity by inhibition of PDK2 ameliorates hepatic steatosis and insulin sensitivity by regulating TCA cycle anaplerosis and ketogenesis. The findings suggest PDK2 is a potential therapeutic target for nonalcoholic fatty liver disease.

AB - Hepatic steatosis is associated with increased insulin resistance and tricarboxylic acid (TCA) cycle flux, but decreased ketogenesis and pyruvate dehydrogenase complex (PDC) flux. This study examined whether hepatic PDC activation by inhibition of pyruvate dehydrogenase kinase 2 (PDK2) ameliorates these metabolic abnormalities. Wildtype mice fed a high-fat diet exhibited hepatic steatosis, insulin resistance, and increased levels of pyruvate, TCA cycle intermediates, and malonyl-CoA but reduced ketogenesis and PDC activity due to PDK2 induction. Hepatic PDC activation by PDK2 inhibition attenuated hepatic steatosis, improved hepatic insulin sensitivity, reduced hepatic glucose production, increased capacity for β-oxidation and ketogenesis, and decreased the capacity for lipogenesis. These results were attributed to altered enzymatic capacities and a reduction in TCA anaplerosis that limited the availability of oxaloacetate for the TCA cycle, which promoted ketogenesis. The current study reports that increasing hepatic PDC activity by inhibition of PDK2 ameliorates hepatic steatosis and insulin sensitivity by regulating TCA cycle anaplerosis and ketogenesis. The findings suggest PDK2 is a potential therapeutic target for nonalcoholic fatty liver disease.

UR - http://www.scopus.com/inward/record.url?scp=84989189575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989189575&partnerID=8YFLogxK

U2 - 10.2337/db16-0223

DO - 10.2337/db16-0223

M3 - Article

VL - 65

SP - 2876

EP - 2887

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 10

ER -